India's Pharma Ambition Meets Global Realities
Commerce Secretary Rajesh Agrawal has directed India's pharmaceutical industry to become 80-90% self-sufficient in critical raw materials. This major push aims to build resilient supply chains, reduce reliance on imports—especially from China—and strengthen India's global pharmaceutical standing. The sector has shown resilience, with exports growing 5.6% year-on-year to $28.29 billion in April-February FY26. However, achieving full domestic production faces significant challenges.
Why India Wants More Domestic Drug Ingredients
The urgency for self-reliance comes from global disruptions like the COVID-19 pandemic, which highlighted how fragile India's dependence on imported Active Pharmaceutical Ingredients (APIs), bulk drugs, and intermediates is. This reliance, particularly on China, led to risks in pricing and supply. To address this, the government launched Production Linked Incentive (PLI) schemes in 2020 to encourage large-scale domestic production of key drug components. The goal is to secure supply chains in an unstable world and also to push innovation, moving India beyond generics into high-value areas like biologics and biosimilars. The Nifty Pharma Index has remained largely stable, trading flat year-to-date by late March 2026, reflecting caution in the market.
China's Dominance and Global Reliance on Imports
Meeting the 80-90% self-sufficiency goal is a huge challenge due to the current market setup. China dominates global generic API and intermediate production, with costs 20-30% lower than India's thanks to state support and aggressive pricing. China's increasing share in API filings signals its future grip on drug pipelines. India, though a major volume producer, still imports 65-70% of its APIs and intermediates from China, a figure that rose to 74% in FY25. Other major regions like the US (90% API import reliant) and the EU also struggle with Asian import dependence, leading to drug shortages. While India's API exports slightly exceeded imports in FY25, this doesn't hide deep reliance on specific critical materials. Ongoing global tensions further heighten these supply risks, causing price swings and market uncertainty. India's export growth of 5.6% in April-February FY26, down from 9.4% the previous year, shows the effect of global challenges.
Obstacles to Local Production and Future Growth
Despite government plans like PLI schemes and new drug parks, India's domestic production faces major structural issues. Slow progress is linked to difficulties in acquiring land, getting clearances, and the high costs of building facilities. Many advanced drug ingredients are still imported. China's aggressive pricing, cutting costs by up to 50% on key APIs and KSMs, severely damages India's ability to compete on price. Moving beyond basic generics to high-value biologics and biosimilars demands huge investment in R&D, advanced manufacturing, and skilled workers—areas where China's fast, government-backed expansion and quick approvals pose strong competition. India's R&D spending, typically 7-8% of revenue, trails global rivals, potentially slowing the development of new treatments. Manufacturing being concentrated in a few areas also creates risks of price hikes and shortages if global events worsen.
Outlook: Growth Potential and Key Success Factors
Even with these challenges, India's pharmaceutical sector is set for significant growth. The market is projected to reach $130 billion by 2030, with expected growth of 9-11% for FY2026. The industry is shifting focus towards innovation, complex generics, biosimilars, and specialty products, especially with an estimated $200+ billion opportunity from major drug patent expirations between 2026 and 2032. India's Contract Development and Manufacturing Organizations (CDMOs) are also growing in importance for biologics production due to competitive costs and regulatory standards. Ultimately, the success of India's self-reliance push depends on strong policy execution, consistent R&D investment, and the industry's ability to adapt to global market changes and intense competition from China.